Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through
direct and indirect mechanisms. HBV DNA integration into the host genome occurs at early …

Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it
can only extend limited survival. It is imperative to find a combination strategy to increase …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Obesity has become more prevalent in most developed countries over the past few decades,
and is increasingly recognized as a major risk factor for several common types of cancer. As …

Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma
(HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70 …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death
worldwide. Liver cancer is generally related to hepatitis B or C infection and cirrhosis …

The knowledge and understanding of all aspects of liver cancer [this including
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have …

Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in
response to nutrients, cellular energy stage and growth factors. mTOR is frequently up …